The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•16 April 2026•

1 min read

TG Therapeutics Completes Enrollment for Phase 3 Subcutaneous BRIUMVI Trial

Key Facts

1TG Therapeutics announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI for relapsing forms of multiple sclerosis (RMS).

2Top-line data from the trial is expected by year-end 2026 or the first quarter of 2027.

3Currently approved BRIUMVI is administered as a one-hour intravenous (IV) infusion twice a year.

TG Therapeutics (NASDAQ: TGTX) has successfully completed patient enrollment for its Phase 3 clinical trial evaluating a subcutaneous injection version of BRIUMVI for relapsing forms of multiple sclerosis (RMS). This new delivery method aims to offer patients more flexible dosing options compared to the currently approved intravenous infusion administered twice yearly. Top-line data from the trial is anticipated to be released by late 2026 or the first quarter of 2027. The completion of enrollment marks a significant operational milestone in the company's efforts to enhance its anti-CD20 monoclonal antibody portfolio. While the progress is positive, the extended timeline for clinical results suggests a moderate immediate impact on market volatility.

Sources:

globenewswire.com